Core Laboratories CLB Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.57M+2.9% | $30.39M-5.5% | $32.73M+20.7% | $30.21M+24.2% | $28.73M-24.5% | ||
| $14.7M-0.9% | $14.65M-2.0% | $14.65M-3.4% | $14.73M-4.5% | $14.83M-4.9% | ||
| $8.01M— | $7.14M— | —— | —— | —— | ||
| $482K-87.9% | -$1.42M-111% | $4M— | $1.72M— | $3.97M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $540K+107% | -$2.64M+71.8% | -$2.9M— | -$6.07M— | -$8.1M— | ||
| —— | —— | —— | $4.05M+412% | $4.04M+161% | ||
| —— | —— | -$3.23M— | —— | —— | ||
| $4.14M+82.6% | $1.2M-78.9% | $2.13M+243% | $2.52M+595% | $2.27M+168% | ||
| -$5.94M— | -$5.06M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$134K+39.1% | ||
| -$5.06M-209% | -$3.78M-183% | $50K— | $3.61M— | $4.65M— | ||
| —— | —— | —— | —— | $20.25K+103% | ||
| $34.34M-40.3% | $37.03M-34.3% | $49.7M-10.0% | $54.3M+29.0% | $57.52M+70.7% | ||
| $11.87M+2.2% | $11.21M-5.7% | $11.51M+1.1% | $12.23M+0.9% | $11.62M+1.7% | ||
| $3.28M+38.1% | $3.02M+73.7% | $3.15M+215% | $3.13M+236% | $2.37M+138% | ||
| -$6.39M-61.3% | -$2.23M+65.1% | -$2.04M+61.4% | -$4.92M+39.8% | -$3.97M— | ||
| $1.86M-0.9% | $1.87M-0.4% | $1.87M-0.1% | $1.88M+0.2% | $1.88M+0.4% | ||
| $14.4M+97.7% | $12.43M+134% | $14.67M+571% | $9.86M+347% | $7.28M+224% | ||
| $101M+135% | $48M+9.1% | $42M-16.0% | $47M-58.4% | $43M-77.6% | ||
| $110M+37.5% | $63M-23.2% | $67M-24.7% | $71M-52.0% | $80M-62.3% | ||
| -$264K-3,033% | -$255K— | -$236K-626% | $38K+183% | $9K+122% | ||
| -$27.23M+41.3% | -$31.26M+32.0% | -$43.51M+3.5% | -$35.88M— | -$46.36M— | ||
| —— | —— | —— | —— | —— | ||
| $8.8M-10.5% | $8.18M-24.6% | $8.67M-25.2% | $9.13M-22.7% | $9.83M-14.7% | ||
| $20.69M+29.7% | $18.74M+6.6% | $15.23M— | $16.25M— | $15.95M— | ||
| —— | —— | —— | —— | —— | ||
| $482K-87.9% | -$1.42M-111% | $4M— | $1.72M— | $3.97M— | ||
| $2.2M— | $1.94M— | —— | —— | —— | ||
| -$18K-104% | -$28K-110% | $435K— | $704K— | $446K— | ||
| $4.14M+82.6% | $1.2M-78.9% | $2.13M+243% | $2.52M+595% | $2.27M+168% | ||
| $1.95M-36.5% | $2.43M-21.2% | $4.35M+172% | $4.05M+169% | $3.08M+58.7% | ||
| —— | $3.42M+184% | $2.86M+202% | $2.31M+234% | $1.76M+304% | ||
| —— | —— | —— | —— | -$134K+39.1% | ||
| —— | —— | —— | —— | —— | ||
| $4.03M+108% | $3.38M+196% | $3.81M— | $2.79M— | $1.93M— | ||
| $141K+713% | $150K+850% | -$18K+92.0% | -$23K+89.9% | -$23K-188% | ||
| $6.83M+30.8% | $9.95M+373% | $9.95M+373% | $6.78M— | $5.22M— | ||
| $3.28M+38.1% | $3.02M+73.7% | $3.15M+215% | $3.13M+236% | $2.37M+138% | ||
| -$264K-3,033% | -$255K— | -$236K-626% | $38K+183% | $9K+122% | ||
| —— | $4.08M— | $3.06M— | $2.04M— | $1.02M— | ||
| —— | —— | —— | —— | $2.46M— | ||
| -$5.06M-209% | -$3.78M-183% | $50K— | $3.61M— | $4.65M— | ||
| —— | $3.06M— | $2.3M— | $1.53M— | $765.25K— | ||
| $22.46M-51.1% | $25.82M-42.0% | $38.19M-12.8% | $42.07M+41.3% | $45.9M+108% | ||
| $22.46M-51.1% | $25.82M-42.0% | $38.19M-12.8% | $42.07M+41.3% | $45.9M+108% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Core Laboratories generate?
- Core Laboratories (CLB) generated $34.3M in operating cash flow over the trailing twelve months.
- What is Core Laboratories's free cash flow?
- After $11.9M of capital expenditures, Core Laboratories's free cash flow was $22.5M over the trailing twelve months, down 51.1% year over year.
- Where does Core Laboratories's cash flow data come from?
- Every line is extracted from Core Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
